(Reuters) - Navidea Biopharmaceuticals Inc said its cancer diagnostic agent was effective in identifying the first lymph node reached by the disease in patients with head and neck cancer, paving the way to expand its use in all solid cancers. The company said a safety monitoring committee recommended that the trial be stopped early due to the positive results. ... Credit of the story
No comments:
Post a Comment